Skip to main content
Clinical Trials/NCT05143645
NCT05143645
Completed
Not Applicable

Evaluation of a New Clinical Protocol for Dose Selection of Vancomycin for Continuous Infusion in ICU Patients.

Karolinska University Hospital1 site in 1 country101 target enrollmentStarted: September 1, 2013Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Karolinska University Hospital
Enrollment
101
Locations
1
Primary Endpoint
Time (days) from start of treatment to first measurement of a plasma vancomycin concentration between 20 and 25 mg/mL

Overview

Brief Summary

This observational study prospectively collect data on chosen dosing, renal function, measured plasma concentrations and adherence to the recommended clinical protocl for ICU patients treated with continuous vancomycin infusion.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Start of continuous vancomycin infusion during the course of intensive care and at least one measurement of plasma concentration.

Exclusion Criteria

  • Vancomycin treatment within 96 h before admission to the unit.
  • Vancomycin treatment started with intermittent bolus infusions.

Outcomes

Primary Outcomes

Time (days) from start of treatment to first measurement of a plasma vancomycin concentration between 20 and 25 mg/mL

Time Frame: Until the end of treatment or discharge from unit

The title is a full description.

Relationship between time to intended concentration (15-20 mg/L) and adherence to the dosing protocol (% complete adherence).

Time Frame: Until the end of treatment or discharge from unit

For each patient the actually administired dose of vancomycin will be compared to the recommendation in the dosing protocol. The time to the intended concentration will be compared between patients with 100% adherence to the recommendations and for patients with dosing not following the recommendations.

Secondary Outcomes

  • Percentage of the total treatment duration with the intended plasma concentration 15-20 mg/L.(Until the end of treatment or discharge from unit)
  • Relationship between Percentage of the total treatment duration with the intended plasma concentration (15-20 mg/L) and adherence to the dosing protocol.(Until the end of treatment or discharge from unit)

Investigators

Sponsor
Karolinska University Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Johan Petersson

Senior ICU Consultant

Karolinska University Hospital

Study Sites (1)

Loading locations...

Similar Trials